View Profile

Henrique Matos Fernandes de Oliveira Duarte

Junior Researcher at the Glycobiology in Cancer group · Institute for Research and Innovation in Health, University of Porto (i3S)

https://researchid.co/henriqueod
@i3s.up.pt
23Scopus Publications
904Google Scholar Citations
12Google Scholar h-index
12Google Scholar i10-index

Research Interests

Glycobiology in cancer; Molecular oncology.

Biography

Junior Researcher and Project Leader at i3S, where he is dissecting the role played by cancer-associated glycosylation signatures in the emergence of molecular resistance to both conventional and targeted therapies in the advanced gastric cancer setting. His work has selected for presentation in multiple international scientific meetings related to Cancer Biology, and has been awarded as both the poster and oral communication (including the Porto Cancer Meeting). He has co-authored 15 publications in internationally recognized peer-reviewed journals (including high profile publications in Trends in Cancer, Oncogene, Cancer Cell, Molecular Aspects of Medicine, FEBS Letters, Plant Biotechnology journal), and 3 book chapters edited by prestigious scientific publishers (Nova Publishers, Wiley and Elsevier).

Education

HOD has an Integrated Master in Bioengineering, with a specialization in Molecular Biotechnology (2014, FEUP/ICBAS) awarded by the University of Porto, for which he was awarded with a Merit Scholarship for Exceptional Achievement as a student of the University of Porto by the Portuguese Ministry of Education (3rd best student of the 2009-2014 class). HOD has an interntional PhD in Molecular and Cellular Biotechnology Applied to Health Sciences (ICBAS/FFUP, University of Porto, 2020), funded by FCT and the European Association for Cancer Research (EACR). Host Institution: Glycobiology in Cancer...

Recent Scopus Publications

  1. Targeting cancer cell sialylation with monosaccharide analogues modulates EGFR in colorectal cancer cells
    Biochimica Et Biophysica Acta General Subjects, 2026
  2. An engineered PD1-Fc fusion produced in N. benthamiana plants efficiently blocks PD1/PDL1 interaction
    Plant Cell Reports, 2025
  3. Glycosylation in Cancer
    Handbook of Experimental Pharmacology, 2025
  4. Patient-derived organoids to study glycosylation dynamics during gastric disease
    Cell Reports, 2025
  5. Plant-derived Durvalumab variants show efficient PD-1/PD-L1 blockade and therapeutically favourable FcR binding
    Plant Biotechnology Journal, 2024

Links